DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.


Journal

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology
ISSN: 1875-0834
Titre abrégé: J Vet Cardiol
Pays: Netherlands
ID NLM: 101163270

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 19 04 2019
revised: 23 12 2019
accepted: 24 12 2019
pubmed: 8 2 2020
medline: 21 10 2020
entrez: 8 2 2020
Statut: ppublish

Résumé

Efficacy of renin-angiotensin-aldosterone system (RAAS) blockade using angiotensin-converting enzyme inhibitors (ACEi) in dogs with preclinical myxomatous mitral valve disease (MMVD) is controversial. Administration of spironolactone (2-4 mg q 24 h) and benazepril (0.25-0.5 mg q 24 h) in dogs with preclinical MMVD, not receiving any other cardiac medications, delays the onset of heart failure (HF) and cardiac-related death. Moreover, it reduces the progression of the disease as indicated by echocardiographic parameters and level of cardiac biomarkers N-terminal pro brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI). 184 dogs with pre-clinical MMVD and left atrium-to-aortic root ratio (LA:Ao) ≥1.6 and normalized left ventricular end-diastolic diameter (LVEDDn) ≥1.7. This is a prospective, randomized, multicenter, single-blinded, placebo-controlled study. Primary outcome variable was time-to-onset of first occurrence of HF or cardiac death. Secondary end points included effect of treatment on progression of the disease based on echocardiographic and radiographic parameters, as well as variations of NT-proBNP and cTnI concentrations. The median time to primary end point was 902 days (95% confidence interval (CI) 682-not available) for the treatment group and 1139 days (95% CI 732-NA) for the control group (p = 0.45). Vertebral heart score (p = 0.05), LA:Ao (p < 0.001), LVEDDn (p < 0.001), trans-mitral E peak velocity (p = 0.011), and NT-proBNP (p = 0.037) were lower at the end of study in the treatment group. This study failed in demonstrating that combined administration of spironolactone and benazepril delays onset of HF in dogs with preclinical MMVD. However, such treatment induces beneficial effects on cardiac remodeling and these results could be of clinical relevance.

Identifiants

pubmed: 32032923
pii: S1760-2734(19)30156-0
doi: 10.1016/j.jvc.2019.12.002
pii:
doi:

Substances chimiques

Angiotensin-Converting Enzyme Inhibitors 0
Benzazepines 0
Peptide Fragments 0
Troponin I 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0
Spironolactone 27O7W4T232
benazepril UDM7Q7QWP8

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial, Veterinary

Langues

eng

Sous-ensembles de citation

IM

Pagination

34-53

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

M Borgarelli (M)

Department Small Animal Clinical Science, Virginia Maryland College of Veterinary Medicine, Blacksburg, VA, USA. Electronic address: mborgarelli@gmail.com.

L Ferasin (L)

Lumbry Park Veterinary Specialists, Alton, Hampshire, UK.

K Lamb (K)

Lamb Statiscal Consulting and Scientific Writing LLC, West St. Paul, MN, USA.

C Bussadori (C)

Clinica Veterinaria Gran Sasso, Milan, Italy.

D Chiavegato (D)

Clinica Veterinaria Arcella, Padova, Italy.

G D'Agnolo (G)

Trieste, Italy.

F Migliorini (F)

Ospedale Veterinario Croce Azzura, Roma, Italy.

M Poggi (M)

Centro Veterinario Imperiese, Imperia, Italy.

R A Santilli (RA)

Clinica Veterinaria Malpensa, Samarate Varese, Italy.

E Guillot (E)

Ceva Santé Animale, Libourne, France.

C Garelli-Paar (C)

Ceva Santé Animale, Libourne, France.

R Toschi Corneliani (R)

Ospedale Veterinario San Francesco, Milan, Italy.

F Farina (F)

Ambulatorio Veterinario Del Parco Margherita, Naples, Italy.

A Zani (A)

Clinica Cardiovet, Livorno, Italy.

M Dirven (M)

Dierenkliniek Rijen, Rijen the Netherlands.

P Smets (P)

Dierenkliniek Rijen, Rijen the Netherlands.

C Guglielmini (C)

Dipartimento di Medicina Animale, Produzione e Salute, Università di Padova, Legnaro Padova, Italy.

P Oliveira (P)

Davies Veterinary Specialists Ltd, Higham Gobion, Hertfordshire, UK.

M Di Marcello (M)

Centro Veterinario Cellatica, Cellatica, Brescia, Italy.

F Porciello (F)

Dipartimento di Medicina Veterinaria, Università Degli Studi di Perugia, Perugia, Italy.

S Crosara (S)

Clinica Veterinaria CMV, Varese, Italy.

P Ciaramella (P)

Dipartimento di Medicina Veterinaria e Produzioni Animali, Università Degli Studi di Napoli Federico II, Naples, Italy.

D Piantedosi (D)

Dipartimento di Medicina Veterinaria e Produzioni Animali, Università Degli Studi di Napoli Federico II, Naples, Italy.

S Smith (S)

Sarah Smith Cardiology Ivy Court, Willington, UK.

S Vannini (S)

Clinica Veterinaria Gran Sasso, Milan, Italy.

E Dall'Aglio (E)

Clinica Veterinaria Milano Sud, Peschiera Borromeo, Milano, Italy.

P Savarino (P)

Facoltà di Medicina Veterinaria di Torino, Ospedale Didattico Veterinario Della Facoltà, Sezione Clinica Medica, Grugliasco, Turin, Italy.

C Quintavalla (C)

Dipartimento di Scienze Mediche Veterinarie, Università di Parma, Parma, Italy.

M Patteson (M)

Heartvets, The Animal Hospital Stinchcombe, Dursley, UK.

J Silva (J)

Clinica Veterinaria Gran Sasso, Milan, Italy.

C Locatelli (C)

Dipartimento di Medicina Veterinaria, Università Degli Studi di Milano, Milan, Italy.

M Baron Toaldo (M)

Dipartimento di Scienze Mediche Veterinarie, Alma Mayor Studiorum, Università di Bologna, Ozzano Emilia, Italy.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH